相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Bcl-2 Is a Therapeutic Target for Hypodiploid B-Lineage Acute Lymphoblastic Leukemia
Ernesto Diaz-Flores et al.
CANCER RESEARCH (2019)
Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signaling
Felix Seyfried et al.
CELL DEATH & DISEASE (2019)
Dual targeting of Hsp90 in childhood acute lymphoblastic leukaemia
Paraskevi Diamanti et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Bcl-2 inhibition sensitizes triple-negative human breast cancer cells to doxorubicin
Touko Inao et al.
Oncotarget (2018)
Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell
Marco Ruella et al.
NATURE MEDICINE (2018)
Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia
S. Peirs et al.
LEUKEMIA (2017)
Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy
Akane Inoue-Yamauchi et al.
NATURE COMMUNICATIONS (2017)
Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia
Guoqing Wei et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2017)
The combination of bortezomib with chemotherapy to treatrelapsed/refractory acute lymphoblastic leukaemia of childhood
Alice Bertaina et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia
Viktoras Frismantas et al.
BLOOD (2017)
Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia
Seong Lin Khaw et al.
BLOOD (2016)
Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy
Rebecca Gardner et al.
BLOOD (2016)
Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
Arend von Stackelberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models
Elizabeth A. Punnoose et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
Hagop M. Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Investigating CD99 Expression in Leukemia Propagating Cells in Childhood T Cell Acute Lymphoblastic Leukemia
Charlotte V. Cox et al.
PLOS ONE (2016)
Improvement of the Outcome of Relapsed or Refractory Acute Lymphoblastic Leukemia in Children Using a Risk-Based Treatment Strategy
Francesco Ceppi et al.
PLOS ONE (2016)
Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies
Alex R. D. Delbridge et al.
NATURE REVIEWS CANCER (2016)
VENETOCLAX: BCL-2 INHIBITION FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
G. Del Poeta et al.
DRUGS OF TODAY (2016)
Antihelminthic benzimidazoles potentiate navitoclax (ABT-263) activity by inducing Noxa-dependent apoptosis in non-small cell lung cancer (NSCLC) cell lines
Lloyd T. Lam et al.
CANCER CELL INTERNATIONAL (2015)
BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells
Sarah E. Alford et al.
CANCER RESEARCH (2015)
Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration
Ching-Hon Pui et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia
Thomas J. Kipps et al.
LEUKEMIA & LYMPHOMA (2015)
Identification of CD34+ and CD34- leukemia-initiating cells in MLL-rearranged human acute lymphoblastic leukemia
Yuki Aoki et al.
BLOOD (2015)
ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia
Sofie Peirs et al.
BLOOD (2014)
Cell and Molecular Determinants of In Vivo Efficacy of the BH3 Mimetic ABT-263 against Pediatric Acute Lymphoblastic Leukemia Xenografts
Santi Suryani et al.
CLINICAL CANCER RESEARCH (2014)
Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia
Rongqing Pan et al.
CANCER DISCOVERY (2014)
Maturation Stage of T-cell Acute Lymphoblastic Leukemia Determines BCL-2 versus BCL-XL Dependence and Sensitivity to ABT-199
Triona Ni Chonghaile et al.
CANCER DISCOVERY (2014)
Role of integrin alpha4 in drug resistance of leukemia
Stephanie Shishido et al.
FRONTIERS IN ONCOLOGY (2014)
Parthenolide eliminates leukemia-initiating cell populations and improves survival in xenografts of childhood acute lymphoblastic leukemia
Paraskevi Diamanti et al.
BLOOD (2013)
Acute B lymphoblastic leukaemia-propagating cells are present at high frequency in diverse lymphoblast populations
Klaus Rehe et al.
EMBO MOLECULAR MEDICINE (2013)
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Andrew J. Souers et al.
NATURE MEDICINE (2013)
Comparison of childhood leukemia initiating cell populations in NOD/SCID and NSG mice
P. Diamanti et al.
LEUKEMIA (2012)
Outcomes after Induction Failure in Childhood Acute Lymphoblastic Leukemia
Martin Schrappe et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Expression of CD34 and CD7 on human T-cell acute lymphoblastic leukemia discriminates functionally heterogeneous cell populations
B. Gerby et al.
LEUKEMIA (2011)
Leukemia-initiating cells in human T-lymphoblastic leukemia exhibit glucocorticoid resistance
Priscilla P. L. Chiu et al.
BLOOD (2010)
Outcome of Patients Treated for Relapsed or Refractory Acute Lymphoblastic Leukemia: A Therapeutic Advances in Childhood Leukemia Consortium Study
Richard H. Ko et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Expression of CD133 on leukemia-initiating cells in childhood ALL
Charlotte V. Cox et al.
BLOOD (2009)
Different forms of cell death induced by putative BCL2 inhibitors
M. Vogler et al.
CELL DEATH AND DIFFERENTIATION (2009)
Elevated p21-Activated Kinase 2 Activity Results in Anchorage-Independent Growth and Resistance to Anticancer Drug-Induced Cell Death
Jerry W. Marlin et al.
NEOPLASIA (2009)
In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties
Christoph le Viseur et al.
CANCER CELL (2008)
Bcl-2 family proteins and cancer
K. W. Yip et al.
ONCOGENE (2008)
Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program
Richard Lock et al.
PEDIATRIC BLOOD & CANCER (2008)
BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia
Victoria Del Gaizo Moore et al.
BLOOD (2008)
Relapse in children with acute lymphoblastic leukemia involving selection of a preexisting drug-resistant subclone
Seoyeon Choi et al.
BLOOD (2007)
beta 1 integrin mediated adhesion increases Bim protein degradation and contributes to drug resistance in leukaemia cells
L. A. Hazlehurst et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized
Mark F. van Delft et al.
CANCER CELL (2006)
Quantitative analysis of bcl-2 expression in normal and leukemic human B-cell differentiation
P Menendez et al.
LEUKEMIA (2004)
分享论文
